# US 2012/0252834 A1 · Novel use and method of rapamycin to treat toxic shock

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252834 A1
- Document ID: US20120252834A1
- Status: Published application
- Kind: A1
- Application number: 13/387,299
- Filed: 2010-08-04
- Published: 2012-10-04
- Earliest claimed: 2009-08-05
- Assignees: The Government of the United States, as represented by the Secretary of the Army
- Inventors: Teresa Krakauer; Marilyn Buckley
- Web page: https://patentgrep.com/patent/US20120252834A1

## CPC

- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0043: {Nose}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Rapamycin is used for prevention and treatment of toxic shock. The toxic shock is induced, for example, by a toxin, such as Staphylococcal enterotoxin A (SEA), Staphylococcal enterotoxin B (SEB), toxic shock syndrome toxin 1 (TSST-I), streptococcal pyrogenic exotoxin A (SPEA), and streptococcal pyrogenic exotoxin C (SPEC).

## Claims

### Claim 1

A method for preventing or treating toxic shock in a subject, comprising administering to said subject a therapeutically effective amount of rapamycin.

### Claim 2 (depends on 1)

The method of claim 1, wherein the toxic shock is induced by exposure to a toxin.

### Claim 3 (depends on 2)

The method of claim 2, wherein the toxin is a Staphylococcal exotoxin.

### Claim 4 (depends on 3)

The method of claim 3, wherein the Staphylococcal exotoxin is Staphylococcal enterotoxin B.

### Claim 5 (depends on 2)

The method of claim 2, wherein the toxin is selected from the group consisting of Staphylococcal enterotoxin A (SEA), Staphylococcal enterotoxin B (SEB), toxic shock syndrome toxin 1 (TSST-1), streptococcal pyrogenic exotoxin A (SPEA), and streptococcal pyrogenic exotoxin C (SPEC).

### Claim 6 (depends on 2)

The method of claim 2, wherein rapamycin is administered in less than 24 hours, less than 23 hours, less than 22 hours, less than 21 hours, less than 20 hours, less than 19 hours, less than 18 hours, less than 17 hour, less than 16 hours, less than 15 hours, less than 14 hours, less than 13 hours, less than 12 hours, less than 11 hours, less than 10 hours, less than 9 hours, less than 8 hours, less than 7 hours, less than 6 hours, less than 5 hours, less than 4 hours, less than 3 hours, less than 2 hours, or less than 1 hour after exposure.

### Claim 7 (depends on 2)

The method of claim 2, wherein more than one dose of rapamycin is administered to the subject during a period of up to 96 hours after exposure.

### Claim 8 (depends on 7)

The method of claim 7, wherein rapamycin is administered at an interval of every 3 hours or every 6 hours.

### Claim 9 (depends on 7)

The method of claim 7, wherein the first dose of rapamycin is administered intranasally.

### Claim 10 (depends on 7)

The method of claim 7, wherein the additional doses of rapamycin after the first dose is administered intraperitoneally.

### Claim 11 (depends on 7)

The method of claim 7, wherein all doses of rapamycin are administered intranasally.

### Claim 12 (depends on 7)

The method of claim 7, wherein the first dose of rapamycin is administered in less than 24 hours after exposure.

### Claim 13 (depends on 1, 2)

The method of claim 1 or claim 2, wherein rapamycin is administered via gastrointestinal administration or via parenteral administration.

### Claim 14 (depends on 1, 2)

The method of claim 1 or claim 2, wherein rapamycin is administered via oral, gavage or rectal administration.

### Claim 15 (depends on 1, 2)

The method of claim 1 or claim 2, wherein rapamycin is administered via intravenous, intramuscular, intranasal, intraperitoneal, or subcutaneous administration.

### Claim 16

Rapamycin for use in the treatment of toxic shock.

### Claim 17 (depends on 16)

The use of claim 16, wherein the toxic shock is induced by exposure to a Staphylococcal exotoxin.

### Claim 18 (depends on 16)

The use of claim 16, wherein the toxic shock is induced by exposure to a toxin selected from the group consisting of Staphylococcal enterotoxin A (SEA), Staphylococcal enterotoxin B (SEB), toxic shock syndrome toxin 1 (TSST-1), streptococcal pyrogenic exotoxin A (SPEA), and streptococcal pyrogenic exotoxin C (SPEC).

### Claim 19

Use of rapamycin for the manufacture of a medicament for the treatment of toxic shock.

### Claim 20 (depends on 19)

The use of claim 19, wherein the toxic shock is induced by exposure to a Staphylococcal exotoxin.

### Claim 21 (depends on 19)

The use of claim 19, wherein the toxic shock is induced by exposure to a toxin selected from the group consisting of Staphylococcal enterotoxin A (SEA), Staphylococcal enterotoxin B (SEB), toxic shock syndrome toxin 1 (TSST-1), streptococcal pyrogenic exotoxin A (SPEA), and streptococcal pyrogenic exotoxin C (SPEC).
